Render Target: STATIC
Render Timestamp: 2024-11-21T14:13:22.134Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:18:59.965
Product last modified at: 2024-10-16T18:45:08.771Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

MIF Antibody #88186

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 12
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    MIF Antibody recognizes endogenous levels of total MIF protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr100 of human MIF protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    MIF (macrophage migration inhibitory factor) is a pleiotropic cytokine that stimulates pro-inflammatory, chemotactic, and growth responses in cells (1). MIF binds its cognate receptor (a CD74/CD44 complex) to activate multiple signaling pathways such as Src, ERK, MAPK, Akt, and suppress p53-induced apoptosis (2). The interaction of MIF with non-cognate chemokine receptors CXCR2 and CXCR4 promotes chemotaxis that enables recruitment of monocytes/neutrophils and T cells (3). During an innate immune response, MIF has been shown to repress the inhibitory effects of glucocorticoids on macrophages and T cells, thus promoting host inflammation and immunity (4). MIF may also play roles in the progression of other disease processes, including cancer cell proliferation and metastasis, and angiogenesis (5), atherosclerotic plaque formation following myocardial ischemia (6), and autoimmune pathogenesis (7). MIF has thus been proposed as a promising therapeutic drug target for multiple indications.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.